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Abstract
Background: Targeted preventive chemotherapy of individuals with progressive subclinical (incipient) disease before it
becomes contagious would break the chain of tuberculosis transmission in high endemic regions. We have studied the
ability of a skin test response to ESAT-6 and CFP10 (E6/C10) to predict later development of tuberculosis disease in the
guinea pig model.
Methods and Findings: Guinea pigs, either vaccinated with BCG or unvaccinated, were infected with a low dose of
Mycobacterium tuberculosis by the aerosol route and the development of delayed type hypersensitivity responses to E6/C10
and to purified protein derivative (PPD) were followed until the onset of clinical disease. We demonstrated a negative
correlation between the size of the skin test response and the time to the onset of clinical disease; a large E6/C10 skin test
response correlated to a shorter survival time post skin testing, while a small E6/C10 skin test reaction correlated with a
longer survival time (r=20.6 and P,0.0001). No correlation was found using PPD.
Conclusions: Our data suggest that it may be possible to develop a prognostic skin test based on E6/C10 that will allow the
identification of individuals with incipient disease, who have the highest risk of developing active tuberculosis in the near
future.
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Introduction
The global tuberculosis (TB) epidemic is continuously fuelled by
transmission of Mycobacterium tuberculosis (MTB) before the patient is
diagnosed [1] This problem is exacerbated by the unpredictable
emergence of new cases arising from the enormous pool of latent
TB. The specific detection of latent M. tuberculosis infection (LTBI)
has recently become possible with the new blood assays; the
ELISA based assay QuantiFERON-TB Gold (Cellestis, Australia)
and the ELISPOT based assay T-SPOT.TB (Oxford Immunotec,
United Kingdom). These interferon gamma (IFN-c) release assays
(also known as IGRAs) are based on measurement of IFN-c
release from peripheral blood cells after stimulation with the MTB
specific antigens; early secreted antigen target 6 (ESAT-6) and
culture filtrate protein 10 (CFP10) [2]. In developed countries
these IGRAs are being used as tools for contact tracing and to
support the decision to initiate preventive therapy for LTBI as they
have proved more specific and informative than the Tuberculin
skin test (TST) [3]. The priorities in high endemic regions are,
however, very different and emphasis is often placed on
identification and chemotherapy of patients with active TB, as
these cases are already infectious and thus the major source of
transmission and new cases. Furthermore, the immense numbers
of latently-infected individuals in these regions makes identification
and treatment of all latent infections virtually impossible with
existing resources. On a global level, preventative therapy is
recommended by the World Health Organization (WHO) only for
HIV-infected persons who have a coincident latent tuberculosis
infection or who are at high risk of exposure e.g household
contacts of patients with confirmed tuberculosis [4]. However, the
development of a prognostic marker for TB would allow treatment
of the small fraction of latently infected individuals in high
endemic regions most at risk of developing contagious TB. By
initiating preventive treatment only for those with a high risk of
incipient disease, breaking the chain of MTB transmission
becomes a realistic prospect, which would contribute greatly to
global TB control efforts.
Expression and secretion of ESAT-6 and CFP10 are tightly
linked to the growth of M. tuberculosis and there is increasing
evidence that cell mediated immune (CMI) responses to ESAT-6
correlate closely with bacterial replication in animal models, both
with regard to bacterial numbers and with regard to the
development of pathology [5,6]. Furthermore, a small study in
recently-exposed, healthy contacts reported an association be-
tween a strong IFN-c response to ESAT-6 and the risk of
developing TB in the 1–2 years after exposure when compared to
exposed contacts with low ESAT-6 responses [7].
In the present study we hypothesized that a skin test reaction
induced by a combination of ESAT-6 and CFP10 (E6/C10) could
be used as a marker for incipient disease in the highly sensitive
guinea pig model. Bacille Calmette-Gue ´rin (BCG) vaccination
prolongs the lifespan of MTB infected guinea pigs and this model
has therefore been used extensively for vaccine testing purposes
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development of active disease [8,9]. In addition to vaccine
evaluation, the guinea pig model has been widely used for the
development,testingand standardizationofskintestreagentssuchas
purified protein derivative (PPD). The use of ESAT-6 and CFP10 as
skintestreagentshavealreadybeendescribedinthismodel,inwhich
a combination of these two molecules proved a specific and sensitive
reagent for the detection of TB infection [10].
We demonstrate that in a group of BCG vaccinated and
unvaccinated guinea pigs with a wide range of lifespan post TB
infection,thesizeoftheskintestreactiontoE6/C10(butnottoPPD)
early after infection, predicts the time period before development of
clinical disease. Our data suggest that it would be possible to develop
a prognostic skin test based on these specific antigens; and that
individuals with the highest risk of later developing active TB could
be identified based on the size of their ESAT6/CFP10 skin test.
Combined with targeted chemotherapy, this approach offers the
possibility of breaking the cycle of MTB transmission by treating
high-risk individuals before they become infectious.
Materials and Methods
Antigens
ESAT-6 and CFP10 were produced as HIS-tagged recombinant
proteins in E. coli as described previously. Briefly, the genes were
cloned into the pMCT6 expression vector and the proteins
purified in the presence of 8 M urea by metal ion affinity
chromatography on a Ni+ column followed by an anion exchange
column [11,12]. The endotoxin levels for both of the proteins were
,50 EU/mg.
Animals
Outbred female Dunkin Hartley guinea pigs (weighing 250–
300 g) were purchased from Harlan Scandinavia (Allerød, Den-
mark). After infection, the animals were housed in cages contained
within laminar flow safety enclosures in a biosafety Level III
facility and provided with irradiated food and filtered drinking
water. The use of guinea pigs was conducted in accordance with
the regulations set forward by the Danish Ministry of Justice and
the animal protection committees and in compliance with
European Community Directive 86/609 and the U.S Association
for Laboratory Animal Care recommendations for the care and
use of laboratory animals.
Experimental infection and vaccination
Vaccinations were performed by subcutaneous injection of
0.5 ml (5610e4 CFU) Mycobacterium bovis BCG (strain Danish
1331, Statens Serum Institut, Copenhagen, Denmark). The
animals were infected with M. tuberculosis eight weeks after BCG
vaccination.
M. tuberculosis strain Erdman was grown in 37uC on modified
Sauton medium enriched with 0.5% sodium pyruvate and 0.5%
Glycose. The animals were infected by the aerosol route with 10–
20 CFU M. tuberculosis strain Erdman using a Gas-Col
TM
nebuliser [13]. The development of disease was followed by
weighing the guinea pigs once to twice a week. Each animal was
euthanized, according to animal care guidelines, when it had lost
15% of body weight compared to the maximum weight or if other
signs of severe illness were observed such as fatigue, breathing
problems or anorexia.
Skin testing
Guinea pigs were divided into groups of five to seven animals
and tested by intradermal injection on the flank with 0.1 ml of
reagent diluted in endotoxin-free phosphate buffered saline (PBS).
All animals were tested with PPD, E6/C10, ESAT-6, CFP10 and
PBS. The locations of the skin tests were randomised and the
diameters of the erythema were read after 24 hours in a blinded
manner by two independent readers. The variation between the
two readings was always less than 10% and the results were
expressed as the mean of the two readings. A mean reaction
diameter of 5 mm was regarded as positive. The PPD RT23
(Statens Serum Institut, Denmark) was used at a dose of 10 T.U (1
T.U=0.02 ug). The E6/C10 was used at a concentration of 1ug
ESAT-6+1 ug CFP10 mixed together in 0.1 ml PBS.
Pilot experiments in uninfected animals revealed that sensitiza-
tion by E6/C10 skin-testing can occur if the animals are
repeatedly skin-tested with time interval between injections of
4 weeks or less (Weldingh, unpublished data). To avoid sensitiza-
tion, the experiments were planned so that repeated injections
were administered with more than 8 weeks interval and a
maximum of 4 tests were performed for each animal. With this
schedule, no sensitization was observed in the control animals
(data not shown). The skin testing was performed at the following
pre-determined intervals post infection: week 4, 8, 12, 20, 35, and
52. In order to allow for the resting period of 8 weeks, groups were
either tested at week 4, 12, 35 and 52; week 8, 20, 35 and or week
12, 20, 35, 52 post infection. To avoid the negative influence of
skin test anergy often found in advanced stages of disease [14] we
excluded animals which had already starting losing weight (defined
as a weight loss of .50 g over a three week period) before the skin
test was performed.
Statistical methods
For comparison of Kaplan-Meier survival curves, medium
survival time and calculation of hazard ratio the software Prism
4.0 from GraphPad was used. The hazard ratio was calculated
using a logrank test (in some places referred to as the Mantel-
Haenszel logrank test). The non-parametric Spearman correlation
analysis was performed by the Bio-statistics department at Statens
Serum Institut using SAS version 9.1. In order to perform a
nonparametric Spearman correlation analysis only one (the first)
data point from each animal was included. The correlation
coefficient r was computed using Fisher’s z transformation. A P
value less than 0.05 was considered significant.
Results
Skin test responses in vaccinated versus non-immunized
guinea pigs
Guinea pigs are highly susceptible to TB but a BCG vaccination
prior to infection can delay the onset of disease by approximately
6–7 weeks. After an aerosol infection with MTB, the number of
bacteria in the lungs of BCG vaccinated animals is approximately
20–30 times lower than in unvaccinated animals measured at week
7 and 13 after infection (data not shown). Using this animal model
we monitored and compared the development of skin test
responses from M. tuberculosis challenge to the onset of disease in
susceptible (non BCG vaccinated) and partly protected animals
(BCG vaccinated). Weight loss was used as an objective non-
invasive parameter for onset of clinical disease and the guinea pigs
were euthanized after a loss of 15% of their maximum weight (data
not shown). In addition, the guinea pigs were observed daily for
sign of disease such as anorexia, fatigue and breathing problems
and if any abnormalities were observed, the animals were
euthanized.
Survival curves from the BCG vaccinated (n=14) and the
unvaccinated (n=14) groups of guinea pigs are shown in figure 1A.
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after infection and 93% (13 out of 14) of the animals in this group
were euthanized by week 31. The development of disease was
delayed in the BCG vaccinated animals-in this group, the first
animal was euthanized at week 19. The median survival time for
the non-vaccinated group was 21 weeks compared to 36.5 weeks
for the BCG vaccinated animals and the survival curves for the
naı ¨ve and the BCG vaccinated animals were significantly different
(log rank test; p=0.0068). At termination of the experiment at
week 58 post infection, four animals in the BCG vaccinated group
and one animal in the naı ¨ve group were still alive.
The delayed disease development in the BCG vaccinated
animals allowed evaluation of skin reactions in different stages of
the infection and the E6/C10 and PPD induced skin test reaction
was followed at various time points after infection (figure 1, B+C).
For longitudinal evaluation of the development of skin test
reactions a maximum of 4 tests with more than 8 weeks interval
were performed for each animal and with this schedule, no
sensitization was observed in the control animals (data not shown).
After BCG vaccination and prior to M. tuberculosis infection all of
the tested (n=7) BCG vaccinated animals were positive to a PPD
skin test (mean of 8 mm), while none of the naı ¨ve animals were
PPD positive at this time point. As expected, neither BCG
vaccinated nor naive animals responded to the E6/C10 skin test
prior to infection, using a 5 mm cut-off.
Four weeks after infection all animals tested (n=14) gave a
positivePPD skintest,regardlessoftheirBCGvaccinationstatusand
in accordance with already published studies [10]. Throughout the
observation period of 58 weeks the PPD induced skin reaction
increased to a maximum of 12 mm for the BCG vaccinated animals
which was in the same range as reactions in the non-vaccinated
animals (mean diameter of 10.5 mm). Skin test responses in the non-
vaccinated animals were not measured after week 20 due to the
development of severe clinical disease in this group.
Four weeks post infection E6/C10 induced a positive skin
reaction in all non-vaccinated animals tested (n=7) with a mean of
12 mm and the animals remained positive to E6/C10 throughout
the observation period of 20 weeks until the animals were
euthanized. In contrast to this, only 1 out of 7 in the BCG
vaccinated group was positive to E6/C10 four weeks after
infection whereas all animals (7 out of 7) were PPD positive at
the same time. The mean E6/C10 skin test response increased in
the BCG vaccinated group during the remainder of the
experiment from a mean of 5 mm at week four, reaching a mean
of 14 mm at week 52 (figure 1B). The percentage of E6/C10
positive animals in the BCG vaccinated group also increased as the
disease developed. Up to week 12 post-infection, only 29% (2 out
of 7) of the BCG vaccinated animals were positive (.5mm) to E6/
C10. At week 20 after infection, the time point where animals in
the BCG vaccinated group started succumbing to the disease, E6/
C10 induced a positive skin test response in 71% (6 out of 7) of the
tested animals and when the experiment was terminated at week
58, all of the surviving five animals were positive by the E6/C10
skin test. Neither PPD nor E6/C10 induced a skin test response in
the non-infected control animals (data not shown).
Correlation between skin test reaction and survival time
post skin test
Our experiment showed that non-immunized animals devel-
oped a positive E6/C10 skin test response soon after infection and
remained skin test positive until the animals were euthanized due
to progressive disease. In contrast, the BCG-vaccinated group of
animals initially controlled the disease and had a markedly lower
E6/C10 skin test reaction size the first 12 weeks after infection.
Figure 1. Survival curves and skintest responses in M.
tuberculosis infected guinea pigs. Survival curves of BCG vaccinated
guinea pigs (triangles) and unvaccinated guinea pigs (open squares)
after M. tuberculosis infection. The animals were sacrificed when they
had lost 15% of the maximum weight or had clinical symptoms
indicative of severe TB (Fig 1A). Mean skin test reaction (+/2SEM) for M.
tuberculosis-infected unimmunized and BCG vaccinated guinea pigs
(n=7), measured as erythema after intradermal injection of 2 ug E6/C10
(Fig. 1B) or 10 T.U. PPD (Fig. 1C). Each animal received a maximum of 4
tests with more than 8 weeks interval and this schedule did not
sensitize naı ¨ve animals. The experiment was repeated twice with the
same overall result and data shown for a representative experiment.
doi:10.1371/journal.pone.0001978.g001
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developed a positive E6/C10 skin test reaction and the mean of
the skin reaction continued to increase up to the point where the
animals were euthanized. We therefore investigated if a correlation
existed between the size of the skin test reaction and survival time
post skin test for the individual animals. This analysis was based on
the first skin test measurement for each animal and we pooled data
for the two groups to get a larger sample size for the total analysis
(figure 2A). This analysis demonstrated a clear negative correlation
between the magnitude of the skin test response and survival time.
This was confirmed by a Spearman’s rank correlation test;
r=20.6 and P,0.0001. Also a statistical analysis at a fixed test
time point, i.e. the Spearman’s correlation test of data from only
week 4, 8 or 12 post infection gave a statistically significant
correlation between skin test size and survival time (week 4:
r=20.59, P=0.0046 and 95 % confidence interval: 20.82, 20.2)
but with larger confidence interval compared to the analysis with
all 44 animals included. No correlation between the magnitude of
the skin test response and survival time after infection was found
using PPD as an antigen; Spearman r=0.27 and P=0.095,
figure 2B.
Discussion
In developed countries, targeted tuberculin testing for LTBI has
long been a strategic component of TB control and individuals
thought to be at high risk of developing TB are offered treatment
[15]. This includes recent contacts and in particular those with
clinical conditions that are associated with an increased risk of
progression of LTBI to active TB (e.g HIV infection). However, in
TB endemic regions with widespread transmission it is much more
complicated to identify recent exposure and due to the high
prevalence of LTBI (up to 80% of adults [16]) the approach of
offering treatment to all infected individuals is not feasible. Our
study suggests that a more targeted approach may be possible and
that the size of an E6/C10 induced skin test response may identify
incipient disease before onset of clinical TB. This concept is not
unprecedented–TB-endemic countries routinely use a higher cut-
off for positivity in the TST than low endemic countries based on
the recognition that the magnitude of the response correlates with
relative risk, albeit poorly.
We used the guinea pig model for a proof of concept study and
took advantage of the fact that in outbred Dunkin Hartley Guinea
pigs, BCG vaccination resulted in a significantly delayed onset of
symptoms and prolonged survival after infection. Importantly, as
these animals came from a genetically variable outbred colony, both
vaccinated and unvaccinated cohorts differed markedly and had a
wide range insurvival time after infection, as documented previously
in numerous studies [13,9]. In the present study, this individual
variation allowed the investigation of the relationship between
clinical outcome and skin test size at the level of the individual
animal. Wedemonstrateda clear associationbetweenthemagnitude
of the skintest response to E6/C10 and the subsequent development
of clinical disease and a large skin test response soon after infection
was found to correlate with a shorter period before onset of disease.
The difference in response patterns for the vaccinated and the naı ¨ve
animals was particularly prominent inthe early phase after infection.
Interestingly,this correlation was not relatedto the skintest per se, as
the PPD skin test response was high throughout the infection period
in all animals (p=0.095) in line with what has already been
published [5,17].
Our study was limited by the risk of sensitization by multiple
skin tests and it was therefore not possible to follow the
development of the skin test response on an individual level for
the animals. In addition, the study did not have statistically power
to define a skin test cut off for incipient disease.
Our finding extends a number of recent reports from animal
models on the use of ESAT-6 induced IFN-c as an immunological
marker that predicts disease progression. In Dietrich et al. [6] a
number of subunit vaccines were tested for efficacy against infection
with M. tuberculosis and a striking correlation was observed between
the magnitude of a post challenge ESAT-6 IFN-c response and the
subsequent outcome of disease. In a study by Vordermeier et al [5],
cattle were experimentally infected with M. bovis and the ESAT-6
specific IFN-c responses were followed until the animals were
euthanized. Again, disease severity, measured by pathology
Figure 2. Relationship between disease outcome and skin test
response to E6/C10 and PPD. Depicted is the size of the skin test
reaction to E6/C10 (figure A) and PPD (figure B) against weeks of
survival post skin testing for each animal. Each symbol represents a skin
reaction from one animal tested either at week at 4, 8 or 12 weeks post
infection (the first skin test for each animal). There is a negative
correlation between E6/C10 skin test response and survival time post
skin testing (P,0.0001) but no correlation between PPD responses and
survival (P=0.095). Triangles represent data points from BCG vaccinated
animals and open squares represent data points from naı ¨ve animals.
doi:10.1371/journal.pone.0001978.g002
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ed to the magnitude of the ESAT-6 specific response.
Although data from humans addressing this correlation are still
limited, one small study clearly demonstrated that the magnitude
of the ESAT-6 specific IFN-c response in recently exposed healthy
contacts correlated with disease status one year later [7].
Consistent with this, in a large study involving 1052 healthy
household contacts from the Gambia it was found that the number
of cells producing IFN-c in response to PPD and ESAT-6
correlated with the level of exposure to M. tuberculosis, even though
this was just a trend for ESAT-6 (p=0.08) [18]. Importantly, no
such relationship across the exposure gradient was found for the
TST. It might seem paradoxical that immune responses to ESAT-
6, an antigen with documented vaccine efficacy in animal models
[13] can serve as a marker for failing immunity. In most cases, an
early induction (before the infection is established) of a vaccine
driven ESAT-6 immune response leads to the suppression of
infection and the subsequent down regulation of the immune
response. In some individuals, however, the bacteria survive by
manipulating the host’s immune response [19]. As ESAT-6 is
secreted by the replicating bacteria [20,21], the infection driven
immune responses to this antigen in susceptible individuals
therefore correlates with the progression of the infection.
It is estimated that on average, each new TB case can infect up
to 10 susceptible contacts before diagnosis [22] and with 8.9
million TB cases in 2004, an enormous number of new infections
occurs each year [23]. 80 % of all cases are found in the 22
highest-burden countries in the developing world and due to the
continuous reactivation of the disease in latently infected
individuals, it is an extremely difficult task to break the cycle of
infection. It would demand huge investments to implement the
IGRAs in areas where the health care systems are generally of a
poor standard and the resources limited. In this context, a novel
skin test may have unique advantages compared to IGRAs. It is
completely independent of laboratory facilities and can therefore
be performed and evaluated on-site even in populations where
blood sampling remains problematic for practical reasons (for
example in young children) or on religious grounds. Furthermore,
due to the existing widespread use of the TST, the health care
personnel in TB endemic areas are in most cases already qualified
and experienced in performing and evaluating skin tests.
We have recently completed a double-blind randomized Phase I
study comparing ESAT-6 to the TST in healthy volunteers and
previously treated TB patients [24]. ESAT-6 was found to be both
safe and highly biologically active but interestingly no statistically
significant association existed between the in-vitro IFN-c response
and the ESAT-6 skin test responses. The reason for this difference
may reflect difference in the kinetics, homing potential or immune
cell subsets involved in the biological functions measured in the
two tests.
We are currently planning clinical studies to define the skin test
dose and cut off value giving the highest predictive value for
subsequent disease. In the light of the results in the present study, it
is our hope that it may be possible to establish one cut off value for
infection and a higher cut off value for incipient disease. In
addition, it remains to be investigated if skin test size can be used
as a single criterion or whether serial testing and conversion is
necessary for prognosis of TB disease, as recently discussed
elsewhere [25]. This would resemble the use of TST conversion to
identify persons of increased risk-such as, for example, the periodic
screening of health care workers which although far from ideal
remains a useful component of TB control programmes in many
countries.
The development of a test that can predict the 5–10% of a
latently infected population at the highest risk of developing TB
would change current practice dramatically and allow the
prioritization of treatment within the population. This would lead
to the best use of the scarce resources available and offer us the
possibility of breaking the cycle of transmission. Short of a new
vaccine, which is active against latent TB, such an approach offers
us the best hope of controlling the global problem of LTBI.
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